Tomas Hanke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5304140/publications.pdf

Version: 2024-02-01

119 papers	5,676 citations	87888 38 h-index	85541 71 g-index
122 all docs	122 docs citations	122 times ranked	4591 citing authors

#	Article	IF	Citations
1	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine, 1998, 4, 397-402.	30.7	640
2	Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. Journal of Virology, 1999, 73, 7524-7532.	3.4	288
3	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. PLoS ONE, 2007, 2, e984.	2.5	247
4	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. Journal of Virology, 2006, 80, 4717-4728.	3.4	220
5	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Journal of General Virology, 2004, 85, 911-919.	2.9	206
6	Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.. Nature Medicine, 2000, 6, 951-955.	30.7	190
7	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475.	8.2	188
8	Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nature Immunology, 2017, 18, 762-770.	14.5	147
9	DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine, 1998, 16, 426-435.	3.8	125
10	Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. Journal of General Virology, 2007, 88, 1-12.	2.9	118
11	Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine, 2006, 24, 417-425.	3.8	117
12	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	8.2	107
13	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet, The, 2020, 395, 888-898.	13.7	98
14	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine, 2007, 25, 2120-2127.	3.8	96
15	A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. Journal of Translational Medicine, 2015, 13, 60.	4.4	84
16	Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine, 2008, 26, 2788-2795.	3.8	83
17	Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine. Journal of Virology, 2006, 80, 4705-4716.	3.4	80
18	Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Molecular Therapy - Methods and Clinical Development, 2019, 12, 32-46.	4.1	74

#	Article	IF	Citations
19	Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial. PLoS ONE, 2014, 9, e101591.	2.5	72
20	A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. Journal of General Virology, 2002, 83, 75-80.	2.9	72
21	Long peptides induce polyfunctional T cells against conserved regions of HIVâ€1 with superior breadth to singleâ€gene vaccines in macaques. European Journal of Immunology, 2010, 40, 1973-1984.	2.9	71
22	Critical Role of Endoplasmic Reticulum Aminopeptidase 1 in Determining the Length and Sequence of Peptides Bound and Presented by HLAâ€“B27. Arthritis and Rheumatology, 2014, 66, 284-294.	5.6	71
23	Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine, 2002, 20, 1995-1998.	3.8	62
24	Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges. PLoS Pathogens, 2011, 7, e1002041.	4.7	62
25	Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opinion on Biological Therapy, 2014, 14, 601-616.	3.1	57
26	Defining the HLA class Iâ€associated viral antigen repertoire from HIVâ€1â€infected human cells. European Journal of Immunology, 2016, 46, 60-69.	2.9	57
27	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Frontiers in Immunology, 2020, 11, 823.	4.8	55
28	Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ Tâ€„cell responses. European Journal of Immunology, 2005, 35, 2532-2540.	2.9	54
29	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). EClinicalMedicine, 2019, 11, 65-80.	7.1	52
30	Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5682-5687.	7.1	51
31	Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine, 2007, 25, 3277-3283.	3.8	50
32	Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine. Journal of Virology, 2012, 86, 4082-4090.	3.4	50
33	Construction and immunogenicity in a primeâ€“boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. Journal of General Virology, 2003, 84, 361-368.	2.9	49
34	Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. Journal of General Virology, 2006, 87, 399-410.	2.9	49
35	Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding. Journal of Virology, 2007, 81, 9408-9418.	3.4	47
36	Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses. PLoS Pathogens, 2015, 11, e1004658.	4.7	42

#	Article	IF	Citations
37	Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. Journal of General Virology, 2005, 86, 349-354.	2.9	40
38	DNA vaccines against human immunodeficiency virus type 1. Immunological Reviews, 2004, 199, 144-155.	6.0	39
39	Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16061.	4.1	39
40	Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine, 2005, 23, 1507-1514.	3.8	38
41	MVA as a vector for vaccines against HIV-1. Expert Review of Vaccines, 2004, 3, S89-S97.	4.4	37
42	CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. Retrovirology, 2018, 15, 46.	2.0	37
43	Evaluation of the immunogenicity and impact on the latent HIVâ€‘1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapyâ€treated subjects. Journal of the International AIDS Society, 2017, 20, 21171.	3.0	36
44	Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms ofin vivo immune interference. European Journal of Immunology, 2007, 37, 566-577.	2.9	35
45	Blocking Development of a CD8+ T Cell Response by Targeting Lymphatic Recruitment of APC. Journal of Immunology, 2009, 182, 2425-2431.	0.8	35
46	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. Aids, 2012, 26, 275-284.	2.2	35
47	Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Molecular Therapy, 2016, 24, 375-384.	8.2	35
48	Control of HIV-1 replication in vitro by vaccine-induced human CD8+ T cells through conserved subdominant Pol epitopes. Vaccine, 2016, 34, 1215-1224.	3.8	35
49	Mice Chronically Infected with Chimeric HIV Resist Peripheral and Brain Superinfection: A Model of Protective Immunity to HIV. Journal of NeuroImmune Pharmacology, 2012, 7, 380-387.	4.1	33
50	Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells. Journal of Virology, 2015, 89, 5760-5771.	3.4	32
51	Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. Aids, 2005, 19, 1321-1323.	2.2	31
52	Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. European Journal of Immunology, 2006, 36, 2585-2594.	2.9	30
53	STEP trial and HIV-1 vaccines inducing T-cell responses. Expert Review of Vaccines, 2008, 7, 303-309.	4.4	28
54	Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. Journal of Immunological Methods, 2014, 409, 161-173.	1.4	28

#	Article	IF	Citations
55	Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. PLoS ONE, 2011, 6, e20067.	2.5	27
56	Optimizing HIVâ€1â€specific CD8⁺ Tâ€cell induction by recombinant BCG in primeâ€boost regimens with heterologous viral vectors. European Journal of Immunology, 2011, 41, 3542-3552.	2.9	27
57	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Frontiers in Immunology, 2018, 9, 3175.	4.8	27
58	Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. Journal of General Virology, 2003, 84, 203-213.	2.9	27
59	Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS ONE, 2017, 12, e0176418.	2.5	27
60	Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials. Expert Review of Vaccines, 2019, 18, 1029-1041.	4.4	26
61	Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens. Journal of Virology, 2019, 93, .	3.4	26
62	Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine, 2009, 28, 474-483.	3.8	25
63	Safety and Immunogenicity of Novel Recombinant BCG and Modified Vaccinia Virus Ankara Vaccines in Neonate Rhesus Macaques. Journal of Virology, 2010, 84, 7815-7821.	3.4	25
64	Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. Journal of General Virology, 1999, 80, 2621-2628.	2.9	25
65	Broad TCR Usage in Functional HIV-1-Specific CD8+T Cell Expansions Driven by Vaccination during Highly Active Antiretroviral Therapy. Journal of Immunology, 2007, 179, 597-606.	0.8	24
66	Increased detection of proliferating, polyfunctional, HIVâ€1â€specific T cells in DNAâ€modified vaccinia virus Ankaraâ€vaccinated human volunteers by cultured IFNâ€γ ELISPOT assay. European Journal of Immunology, 2009, 39, 975-985.	2.9	23
67	In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Frontiers in Immunology, 2020, 11, 418.	4.8	23
68	Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen. Journal of Virology, 2005, 79, 14822-14833.	3.4	22
69	Novel HIVâ€1 clade B candidate vaccines designed for HLAâ€B[*]5101⁺ patients protected mice against chimaeric ecotropic HIVâ€1 challenge. European Journal of Immunology, 2009, 39, 1831-1840.	2.9	22
70	Novel RecombinantMycobacterium bovisBCG, Ovine Atadenovirus, and Modified Vaccinia Virus Ankara Vaccines Combine To Induce Robust Human Immunodeficiency Virus-Specific CD4 and CD8 T-Cell Responses in Rhesus Macaques. Journal of Virology, 2010, 84, 5898-5908.	3.4	22
71	Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice. Vaccine Journal, 2014, 21, 1565-1572.	3.1	22
72	DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge. Aids, 2013, 27, 2841-2851.	2.2	21

#	Article	IF	Citations
73	Identification of novel HIV-1-derived HLA-E-binding peptides. Immunology Letters, 2018, 202, 65-72.	2.5	21
74	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. PLoS Pathogens, 2019, 15, e1007564.	4.7	20
75	MHC class II invariant chainâ€“adjuvanted viral vectored vaccines enhances T cell responses in humans. Science Translational Medicine, 2020, 12, .	12.4	20
76	Newborn Mice Vaccination with BCG.HIVA²²²+ MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes. Clinical and Developmental Immunology, 2011, 2011, 1-11.	3.3	19
77	HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Molecular Therapy, 2017, 25, 494-503.	8.2	19
78	Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens. PLoS ONE, 2017, 12, e0181382.	2.5	19
79	<scp>T</scp> cells induced by recombinant chimpanzee adenovirus alone and in primeâ€boost regimens decrease chimeric <scp>E</scp>co<scp>HIV</scp>/<scp>NDK</scp> challenge virus load. European Journal of Immunology, 2012, 42, 3243-3255.	2.9	18
80	Engineering new mycobacterial vaccine design for HIVâ€“TB pediatric vaccine vectored by lysine auxotroph of BCG. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14017.	4.1	18
81	Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine, 2010, 28, 7306-7312.	3.8	17
82	A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants. PLoS ONE, 2013, 8, e78289.	2.5	17
83	Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. Vaccines, 2019, 7, 78.	4.4	16
84	Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. Frontiers in Immunology, 2019, 10, 923.	4.8	16
85	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS ONE, 2017, 12, e0181886.	2.5	16
86	Pre-Clinical Development of BCG.HIVACAT, an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG. PLoS ONE, 2012, 7, e42559.	2.5	15
87	Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity. Human Vaccines and Immunotherapeutics, 2017, 13, 1798-1810.	3.3	15
88	HIVâ€1: From escapism to conservatism. European Journal of Immunology, 2011, 41, 3390-3393.	2.9	14
89	MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. Molecular Therapy - Methods and Clinical Development, 2019, 13, 253-264.	4.1	14
90	PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi. Vaccine, 2014, 32, 5801-5808.	3.8	13

#	Article	IF	Citations
91	Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. PLoS ONE, 2018, 13, e0197299.	2.5	13
92	Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine, 2020, 38, 5036-5048.	3.8	13
93	Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice. Vaccine, 2013, 31, 5594-5601.	3.8	12
94	Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. Vaccines, 2020, 8, 360.	4.4	12
95	Growth patterns and their contributing factors among HIVâ€exposed uninfected infants. Maternal and Child Nutrition, 2021, 17, e13110.	3.0	11
96	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. PLoS ONE, 2014, 9, e114709.	2.5	11
97	Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines. Aids, 2014, 28, 2495-2504.	2.2	10
98	Effect of epitope variant co-delivery on the depth of CD8 TÂcell responses induced by HIV-1 conserved mosaic vaccines. Molecular Therapy - Methods and Clinical Development, 2021, 21, 741-753.	4.1	9
99	Altered primary CD8+ Tâ€„cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ Tâ€„cell help. European Journal of Immunology, 2005, 35, 3460-3467.	2.9	8
100	On DNA vaccines and prolonged expression of immunogens. European Journal of Immunology, 2006, 36, 806-809.	2.9	8
101	Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques. Immunity, Inflammation and Disease, 2015, 3, 82-93.	2.7	8
102	Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines. Vaccines, 2020, 8, 28.	4.4	8
103	Development of prophylactic AIDS vaccines: the current state of affairs. Current Opinion in Molecular Therapeutics, 2003, 5, 25-32.	2.8	8
104	Transient IL-10 receptor blockade can enhance CD8+T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen. Human Vaccines and Immunotherapeutics, 2015, 11, 1030-1035.	3.3	7
105	Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya. Vaccines, 2020, 8, 260.	4.4	5
106	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. Molecular Therapy - Methods and Clinical Development, 2019, 14, 148-160.	4.1	4
107	Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice. Vaccines, 2020, 8, 678.	4.4	4
108	A statistical approach to determining responses to individual peptides from pooled-peptide ELISpot data. Journal of Immunological Methods, 2016, 435, 43-49.	1.4	3

#	Article	IF	Citations
109	Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination. Npj Vaccines, 2021, 6, 117.	6.0	3
110	Infant Neutropenia Associated with Breastfeeding During Maternal Antiretroviral Treatment for Prevention of Mother-to-Child Transmission of HIV. Retrovirology: Research and Treatment, 2014, 6, 1.	1.0	1
111	Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsv, in HAART-treated Subjects. AIDS Research and Human Retroviruses, 2014, 30, A190-A190.	1.1	1
112	Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: Mapping of CD8+ T Cell Epitopes. AIDS Research and Human Retroviruses, 2014, 30, A187-A187.	1.1	1
113	The Landscape of Targeted Immune Responses in the HIV-1 Vaccine Field. AIDS Research and Human Retroviruses, 2016, 32, 944-946.	1.1	1
114	Adenovirus DNA Polymerase Loses Fidelity on a Stretch of Eleven Homocytidines during Pre-GMP Vaccine Preparation. Vaccines, 2022, 10, 960.	4.4	1
115	A Pilot Study of the Safety and Inununogenicity of An HIV-1 Clade a Gag/Multiepitope DNA Vaccine, pTHr.HIVA, in HIV-1 Seropositive Subjects Receiving Highly Active Antiretroviral Therapy. Clinical Science, 2003, 104, 54P-54P.	0.0	0
116	Developing HIV-1 vaccines with a positive attitude. Future HIV Therapy, 2008, 2, 213-216.	0.4	0
117	A Novel T-cell Vaccine Eliciting T-cell Specificities Associated with Control of HIV-1 In Humans Is Highly Immunogenic in Mice and Macaques. AIDS Research and Human Retroviruses, 2014, 30, A76-A76.	1.1	0
118	PO 8515â€…CAPACITY BUILDING IN PREPARATION FOR AN HIV VACCINE TRIAL: THE GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT). BMJ Global Health, 2019, 4, A48.1-A48.	4.7	0
119	OC 8499â€…THE T-CELL VACCINE STRATEGY: GLOBALLY RELEVANT AIDS VACCINE EUROPE-AFRICA TRIALS PARTNERSHIP (GREAT). BMJ Global Health, 2019, 4, A10.3-A11.	4.7	0